Tumor-specific transcription factor binding to an activator protein-2/Sp1 element of the urokinase-type plasminogen activator receptor promoter in a first large series of resected gastrointestinal cancers

Clinical Cancer Research

Volumn 9, Issue 6, 2003, Pages 2267-2276

  Schewe, Denis Martin ^a   Leupold, Joerg H ^a   Boyd, Douglas D ^b   Lengyel, Ernst R ^c   Wang, Heng ^b   Gruetzner, Klaus Uwe ^a   Schildberg, Friedrich W ^a   Jauch, Karl W ^a   Allgayer, Heike ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR SP1; UROKINASE RECEPTOR;

ARTICLE; CANCER PATIENT; CANCER SURGERY; CELL SUBPOPULATION; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIGESTIVE SYSTEM CANCER; ELECTROPHORETIC MOBILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MAJOR CLINICAL STUDY; METASTASIS INHIBITION; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TARGETING; STATISTICAL SIGNIFICANCE; TISSUE SPECIFICITY; TRANSACTIVATION; TRANSCRIPTION REGULATION;

ADULT; AGED; AGED, 80 AND OVER; DNA-BINDING PROTEINS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PROMOTER REGIONS (GENETICS); RECEPTORS, CELL SURFACE; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP-2; TRANSCRIPTION FACTORS;

EID: 0037838422     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Ossowski, L., Clunie, G., Masucci, M. T., and Blasi, F. In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J. Cell Biol., 115: 1107-1112, 1991.
2. Blasi, F. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. BioEssays, 15: 105-111, 1993.
3. Dano, K., Andreasen, P. A., Grondahl-Hansen, J., Kristensen, P., Nielsen, L. S., and Skriver, L. Plasminogen-activators, tissue degradation, and cancer. Adv. Cancer Res., 44: 139-266, 1985.
4. Liotta, L. A., Steeg, P. S., and Stetler-Stevenson, W. G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64: 327-336, 1991.
5. Ploug, M., Behrendt, N., Lober, D., and Dano, K. Protein structure and membrane anchorage of the cellular receptor for urokinase-type plasminogen activator. Semin. Thromb. Hemost., 17: 183-193, 1991.
6. Estreicher, A., Muhlhauser, J., Carpentier, J. L., Orci, L., and Vassalli, J. D. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J. Cell Biol., 111: 783-792, 1990.
7. Allgayer, H., Boyd, D. D., Lengyel, E. R., and Heiss, M. M. The urokinase-receptor: molecular regulation and clinical significance. Res. Adv. Cancer, 1: 85-97, 2001.
8. Moller, L. B. Structure and function of the urokinase receptor. Blood Coagul. Fibrinolysis, 4: 293-303, 1993.
9. Cantero, D., Friess, H., Deflorin, J., Zimmermann, A., Bründler, M. A., Riesle, E., Korc, M., and Buchler, M. W. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br. J. Cancer, 75: 388-395, 1997.
10. Jankun, J., Merrick, H. W., and Goldblatt, P. J. Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. J. Cell Biochem., 53: 135-144, 1993.
11. Pedersen, H., Grondahl-Hansen, J., Francis, D., Osterlind, K., Hansen, H. H., Dano, K., and Brünner, M. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res., 54: 120-123, 1994.
12. Duffy, M. J., Reilly, D., O'Sullivan, C., O'Higgins, N., Fennelly, J. J., and Andreasen, P. Urokinase plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res., 50: 6827-6829, 1990.
13. Allgayer, H., Heiss, M. M., and Schildberg, F. W. Prognostic factors in gastric cancer: a review. Br. J. Surg., 84: 1651-1664, 1997.
14. Nekarda, H., Schmitt, M., Ulm, K., Wenninger, A., Vogelsang, H., Becker, K., Roder, J. D., Fink, U., and Siewert, J. R. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res., 54: 2900-2907, 1994.
15. Heiss, M. M., Babic, R., Allgayer, H. Grützner, K. U., Jauch, K. W., Loehrs, U., and Schildberg, F. W. Tumor associated proteolysis and prognosis: New functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J. Clin. Oncol., 13: 2084-2093, 1995.
16. Janicke, F., Schmitt, M., Pache, L., Ulm, K., Harbeck, N., Hofler, H., and Graeff, H. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node negative breast cancer. Breast Cancer Res. Treat., 24: 195-208, 1993.
17. Ganesh, S., Sier, C. F. M., Heerding, M. M., Griffionen, G., Lamers, C. B. H., and Verspaget, H. W. Urokinase receptor and colorectal cancer survival. Lancet, 344: 401-402, 1994.
18. Wang, H., Skibber, J., Juarez, J., and Boyd, D. Transcriptional activation of the urokinase receptor gene in invasive colon cancer. Int. J. Cancer, 58: 650-657, 1994.
19. Shetty, S., Kumar, A., and Idell, S. Posttranscriptional regulation of urokinase receptor mRNA: identification of a novel urokinase receptor mRNA binding protein in human mesothelioma cells. Mol. Cell. Biol., 17: 1075-1083, 1997.
20. Allgayer, H., Wang, H., Wang, Y., Heiss, M. M., Bauer, R., Nyormoi, O., and Boyd, D. Transcription of the urokinase-type plasminogen activator receptor gene through a novel promotor motif bound with an activator protein-2α-related factor. J. Biol. Chem., 274: 4702-4714, 1999.
21. Allgayer, H., Wang, H., Gallick, G. E., Crabtree, A., Mazar, A., Jones, T., Kraker, A. J., and Boyd, D. D. Transcriptional induction of the urokinase receptor gene by a constitutively active Src. Requirement of an upstream motif (-152/-135) bound with Sp1. J. Biol Chem., 274: 18428-18437, 1999.
22. Jessup, J. M., and Gallick, G. E. The biology of colorectal carcinoma. In: R. F. Ozols, G. Steele, and T. J. Kinsella (eds.), Current Problems in Cancer, pp. 261-328. St. Louis: Mosby Year Book, Inc., 1992.
23. Ibañez-Tallon, I., Ferrai, C., Longobardi, E., Facetti, I., Blasi, F., and Crippa, M. Binding of Sp1 to the proximal promoter links constitutive expression of the human uPA gene and invasive potential of PC3 cells. Blood, 100: 3325-3332, 2002.
24. Zannetti, A., Del Vecchio, S., Carriero, M. V., Fonti, R., Franco, P., Botti, G., D'Aiuto, G., Stoppelli, M. P., and Salvatore, M. Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma. Cancer Res., 60: 1546-1551, 2000.
25. Yang, X., Su, K., Roos, M. D., Chang, Q., Paterson, A. J., and Kudlow, J. E. O-linkage of N-acetylglucosamine to Sp1 activation domain inhibits its transcriptional capability. Proc. Natl. Acad. Sci. USA, 98: 6611-6616, 2001.
26. Lipponen, P., Aaltomaa, S., Kellokoski, J., Ala-Opas, M., and Kosma, V. Expression of activator protein 2 in prostate cancer is related to tumor differentiation and cell proliferation. Eur. Urol., 37: 573-578, 2000.
27. Anttila, M. A., Kellokoski, J. K., Moisio, K. I., Mitchell, P. J., Saarikoski, S., Syrjanen, K., and Kosma, V. M. Expression of transcription factor AP-2α predicts survival in epithelial ovarian cancer. Br. J. Cancer, 82: 1974-1983, 2000.
28. Huang, Y., and Domann, F. E. Transcription factor AP-2 mRNA and DNA binding activity are constitutively expressed in SV40-immortalized but not normal lung fibroblasts. Arch. Biochem. Biophys., 364: 241-246, 1999.
29. Qin, H., Sun, Y., and Benveniste, E. N. The transcription factors Sp1, Sp3 and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J. Biol. Chem., 274: 29130-29137, 1999.
30. Wang, F., Duan, R., Chirgwin, J., and Safe, S. H. Transcriptional activation of cathepsin D gene expression by growth factors. J. Mol. Endocrinol., 24: 193-202, 2000.
31. Yan, S., Berquin, I. M., Troen, B. R., and Sloane, B. F. Transcription of human cathepsin B is mediated by Sp1 and Ets family factors in glioma. DNA Cell Biol., 19: 79-91, 2000.
32. Lohi, J., Lehti, K., Valtanen, H., Parks, W. C., and Keski-Oja, J. Structural analysis and promoter characterization of the human membrane-type matrix metalloproteinase-1 (MTI-MMP) gene. Gene (Amst.), 242: 75-86, 2000.
33. Ritchie, S., Boyd, F. M., Wong, J., and Bonham, K. Transcription of the human c-Src promoter is dependent on Sp1, a novel pyrimidine binding factor SPγ, and can be inhibited by triplex-forming oligonucleotides. J. Biol. Chem., 275: 847-854, 2000.
34. Barvian, M. R., Klutchko, S., Hamby, J. M., Kraker, A. J., Moore, C., Hartl, B. J., Lu, G. H., Panek, R. L., Fay, D. W., Doherty, A. M., and Showalter, H. D. H. Development of c-src selective 8H-pyrido[2,3-d]pyrimidin-7-one tyrosine kinase inhibitors via parallel synthesis. Proc. Am. Assoc. Cancer Res., 39: 176, 1998.